PEDIATRICS Vol. 106 No. 5 November 2000, pp. 1006-1012
Effectiveness of a Clinical Pathway for Inpatient Asthma Management
,
From the Divisions of * General Pediatrics,
Pediatric
Pulmonary Medicine, § Pediatric Emergency Medicine, and
Pediatric
Immunology, The Johns Hopkins University School of Medicine, Baltimore,
Maryland.
| |
ABSTRACT |
|---|
|
|
|---|
Background. Clinical pathways for asthma are tools that have the potential to improve compliance with nationally recognized management guidelines, but their effect on patient outcomes has not been documented.
Objectives. To determine the effect of an asthma clinical
pathway on patients' length of stay, use of nebulized
-agonist
therapy while hospitalized, and use of acute care clinics for 2 weeks
after discharge.
Design/Methods. The study was a randomized, controlled trial. Patients between the ages of 2 and 18 years admitted with an asthma exacerbation and not under the care of an asthma specialist were eligible for the study. Patients were randomized either to a conventional ward (control group) or to a ward using the clinical pathway (intervention group). For 2 weeks after discharge, we collected data to determine whether patients visited a health care provider for worsening asthma.
Results. One hundred ten patients (26%) were enrolled.
Control and intervention groups had similar demographic and asthma
severity profiles. The intervention group had an average length of stay 13 hours shorter than did the control group. In addition, at every dosing interval, the intervention group received less nebulized
-agonist therapy. There were no deaths in either group.
Conclusion. A clinical pathway for inpatient asthma
decreased the length of stay and
-agonist medication use with no
adverse outcomes or increased acute-care encounters through 2 weeks
after discharge.
Key words:
asthma,
clinical practice guidelines,
clinical pathways,
health services research.
Asthma is the most common chronic childhood illness in the
United States,1,2 affecting 4.8 million children and
adolescents in 1996.3 Asthma accounts for over 2 million
pediatrician visits per year.2 With an average length of
stay of just under 3 days for each inpatient admission and a cost of
over 1 billion dollars in direct medical expenditures, asthma poses a
considerable economic burden on our health care system.4,5
Many of these hospital admissions can be prevented by aggressive preventive care6,7; guidelines have been in existence for
some time that are rarely adopted in hospital practices.8
Although this report provided comprehensive information about the
pathophysiology of asthma and specific management recommendations, the
information was not provided in a format conducive to the needs of
inpatient multidisciplinary teams caring for these patients.
Clinical pathways are tools that outline a sequence of clinical
evaluations and interventions for patients with specific
conditions.9 These evaluations and interventions ideally
are established from published clinical guidelines. When there is no
published evidence to guide a decision, the clinical pathway uses
expert local or national consensus to choose an appropriate plan of
care. Numerous studies have demonstrated that a well-designed clinical
pathway is an effective means of sustaining quality, while controlling costs in the management of certain disease entities.10-15
Many hospitals have implemented and mandated the use of these tools for
a variety of their high-cost or high-volume diagnoses.16
Our institution recognized the potential improvement in outcomes
afforded by adopting the guidelines published by the National Heart,
Lung, and Blood Institute (NHLBI). Therefore, we assembled a
multidisciplinary team to develop a clinical pathway based on these
guidelines.
Table 1 outlines the key features of our
clinical pathway. Previous studies of asthma clinical pathways have
demonstrated a decrease in laboratory and radiology
charges17 as well as more consistent conversion to metered
dose inhalers in one emergency department (ED)10 and
improved use of spacers and oral steroids in another ED.13
However, none of these studies has shown an effect on the patients' length of stay. The overall goal of our pathway was to improve compliance with the guidelines for managing asthma admissions, and to
improve patient care by coordinating actions among the various
providers who formed our asthma care team. We hypothesized that with
better coordination of care and with the adoption of practices as
outlined in Table 1, length of stay and use of nebulized TABLE 1
-agonists
during admission both would decrease.
Key Features of the Clinical
Pathway
One of the most significant results of our team meetings was a decision
to rethink how we weaned a patient's nebulized
-agonist therapy. In
nearly all cases, nebulized
-agonists were weaned after a physician
assessed the patient and wrote an order to change the frequency of
these medications. Our multidisciplinary team raised 2 concerns. The
first was that the assessment was not standardized, making the weaning
procedure subject to whatever approach was preferred by specific
physicians. The second concern was that residents in training
simultaneously assume the role of primary inpatient care provider,
teacher, administrator, and student. Weaning the nebulized
-agonists
of a patient with asthma is one of many responsibilities in this
setting and has a particularly low priority in the evening and early
morning hours, when fewer staff are available. Similarly, respiratory
therapists are not adequately staffed to assess each patient and
administer each nebulized
-agonist. Attending staff and senior
residents are less available than are interns and would not be likely
to provide assistance in a timely manner. We hypothesized that an
approach using our registered nursing staff to evaluate and modify
nebulized
-agonist therapy might improve the rate and consistency of
weaning. However, this change in practice could either improve or
worsen other outcomes, including length of stay and readmission rates. For example, the pathway could increase the number of subsequent urgent
care, ED, or inpatient encounters for patients who were discharged too
quickly. Therefore, we initiated a study to determine the impact of a
clinical pathway for inpatient asthma management on the patients'
duration of hospitalization, amount of bronchodilator therapy, and
frequency of readmissions within 2 weeks of discharge.
| |
METHODS |
|---|
|
|
|---|
Study Design
This was a randomized, controlled study conducted from the summer of 1995 through the summer of 1997 at Johns Hopkins Hospital, an urban academic medical center. There are ~500 pediatric admissions for asthma annually, accounting for just over 7% of all admissions to the pediatric service. The clinical pathway was constructed over a 4-month period before beginning the study. A pediatric multidisciplinary team, consisting of general hospital-based physicians, pulmonologists, emergency medicine physicians, outpatient physicians, clinical nurses, a respiratory therapists, social workers, and other members of our asthma care team participated actively in the design of the pathway. In addition to the pathway, a weaning protocol was constructed, based on the NHLBI guidelines (Fig 1). Four months before starting the study, all nursing staff on our clinical research (intervention) unit were taught how to assess patients with asthma using a train-the-trainer approach, with 1 attending physician and 4 senior residents as the educators. This group used a standard teaching plan that had been constructed by a nurse educator in our department to train the senior nurses on the intervention unit. These senior nurses then conducted one training session on the unit during each nursing shift, and conducted additional one-on-one sessions as new nurses were hired during the study. The senior residents who helped with training completed their residency before the start of the study and, therefore, were not included in the study. Nurses and physicians at this site were familiar with the design and operation of clinical pathways.
|
The clinical pathway was designed for patients between 2 and 18 years of age, who were being admitted to the hospital with a primary diagnosis of an asthma exacerbation, and who were not cared for by an asthma specialist. Patients meeting these criteria and whose families had a phone or pager were eligible for the study. Patients admitted to the intensive care unit and patients who had previously been enrolled in the study were excluded. Study enrollment also required that inpatient beds be available in both our intervention and control sites at the time of admission, so that randomization could take place.
After written, informed consent was obtained, each patient's family
completed an enrollment questionnaire, after which the patient was
randomized to a bed on either the intervention unit or a control unit.
The control and intervention units were located on different floors
within the hospital. Although housestaff coverage was the same on both
units, there was no exchange of nursing staff between the control and
intervention units. Nurse-to-patient ratios were identical on both
units, with more acutely ill patients receiving a more nursing time
(1:2-3) and more stable patients receiving a bit less time (1:4-5).
Staff demographics and experience in nursing were similar. Patients
admitted to the intervention unit received care according to the
clinical pathway. Nursing staff on the intervention unit assessed
patients before each nebulized
-agonist, using the guidelines in Fig
1. If the patient met criteria for changing the frequency of therapy,
then the nurse notified the house officer on call, who assessed the
patient and determined whether the patient's therapy could be weaned.
If the patient did not meet criteria for weaning, the nurse
administered the treatment and reassessed the patient to ensure that
the patient's symptoms were not worsening. Nursing staff on the
control unit followed our usual standard of care, including obtaining
vital signs before administering each nebulized
-agonist. They did not determine whether patients were ready to be weaned from their medications. However, they would notify the house officer if asked to
before administering a nebulized
-agonist (as was often the case
when house officers were ready to assess a patient for weaning). Control patients received education about the use of an inhaler and
spacer, as well as some coordination of postdischarge care from our
case management team.
After patients were discharged, one of the investigators (K.B.J.) reviewed the chart and the medication administration documentation to record the time the discharge order was written, the actual time of discharge, and details about when and what medications were administered during the hospital stay. Discharge medications were written on a follow-up form, which was given to a research assistant. This person was blinded to the patient's group assignment. The research assistant conducted phone follow-up of each patient at 1 day, 1 week, and 2 weeks after discharge, to determine whether there had been any unscheduled health care encounters related to asthma. For patients who could not be reached by phone at the end of 2 weeks, we reviewed the medical records and computer scheduling system data at our site, as well as those of our affiliated health management organization, for evidence of unplanned encounters related to asthma.
Analysis
The study was designed to evaluate 4 main variables. The first
of these, the duration of hospitalization, was defined as the number
hours that elapsed from the first every 2-hour bronchodilator until the
time the discharge order was written. We chose to use the first every
2-hour nebulized
-agonist as a standard starting point, which also
is a point at which we typically admit patients to a bed outside of
intensive care. The study also evaluated the number of nebulization
therapies, defined as the number of nebulized
-agonists given during
the hospitalization (within the time period above); and the number of
unplanned health care interventions, defined as the number of urgent
care, emergency department, or inpatient encounters related to
worsening symptoms of asthma within 2 weeks of discharge. Finally, the
study examined the hospital charges for each patient.
Data for the first 2 dependent variables were obtained by reviewing the clinical pathway, and the medical record after the patient was discharged. A research assistant obtained data about unplanned health care interventions. Each family completed a survey at the time of enrollment to provide data about the patient's disease severity, medical history, home environment, and socioeconomic status. Hospital charge data were obtained from our inpatient charge database.
Initial sample size was calculated at 120 patients per group to have
80% power to detect a 10% decrease in the number of unplanned health
care interventions, using a 2-tailed
of .05. A sample size of 50 patients per group was required to detect a 20% difference in the
duration of hospitalization using similar parameters. Randomization was
blocked to allow the study to be safely discontinued at 100 patients.
Because of a need to make changes in our practice pattern as described
in the clinical pathway, and because study enrollment was slowing down
attributable to limited bed availability, we elected to terminate the
study after just over 100 patients had been enrolled.
Data were analyzed using the SPSS statistical
package.18
2 and Fisher's exact
tests were used to characterize any differences between our control and
intervention groups as measured by nominal variables, and the
Student's t test was used for interval and ratio data.
Analyses of covariance and multivariate regression techniques were used
to determine the effect, if any, that confounders had on our outcomes
of interest. Institutional review board approval was obtained for this
study.
| |
RESULTS |
|---|
|
|
|---|
Enrollment
During the study, 432 patients met criteria to be enrolled into the study. Of these, 314 patients were admitted on days when a bed was not available on either our intervention or our control units. Therefore, 118 patients were approached to participate in the study. Six of these patients did not wish to participate. In addition, 2 patients who were admitted subsequently asked to be disenrolled from the study and were excluded from analyses, leaving a total of 110 patients, or 26% of the potential enrollees, who participated in the study. One of the patients who disenrolled did so because of conflicting willingness on the part of the parents to be involved in the study. This child had been enrolled in the control group. The other child's parent disenrolled after finding that her child, who also was to be assigned to the control group, would have to wait for an inpatient bed. Both children had uncomplicated inpatient stays.
Control Versus Intervention Characteristics
Table 2 summarizes the demographic and asthma severity characteristics of the control and intervention groups. More intervention patients had received steroids before arrival to the ED (22 vs 10; P = .02). The control patients were younger on average (8.2 vs 6.6 years; P = .04). There was no significant difference between the number of preschool or adolescent patients in either group. Otherwise, the 2 groups were similar. As is shown in Table 2, there was no difference between the 2 groups with respect to common surrogates for disease severity (including school days missed and parent's perception of asthma severity), home pharmacotherapy, reported triggers, or their management in the ED. Both groups had similar pulse oximetry values on arrival to the ED, similar needs for supplemental oxygen at admission, and similar average respiratory rates on admission.
|
Length of Stay and Therapy Differences
The duration of hospitalization was 13 hours shorter for the
patients managed according to the clinical pathway (53.7 vs 40.3 hours;
P < .01). This difference was not affected when
controlling for the administration of steroids before arrival (F = .06), and was independent of patient age (F = 3.2;
P > .05). The clinical pathway group had a larger
percentage of patients discharged within the first 24 hours of
admission (38% vs 14.5%; P < .01), as shown in Fig
2. In addition, there was a significantly
shorter duration of every 2-hour nebulized
-agonist therapy in the
clinical pathway group, as shown in Table
3, with a trend toward a smaller mean
number of nebulized
-agonists at every frequency at which they were
administered. Table 4 shows the effect of
the clinical pathway on other variables of interest. There was a
significant difference between the routine (room) charges and
medication administration charges between the 2 groups. In addition,
there was a trend toward lower mean medication and laboratory tests
charges between the groups. There was no significant difference in the
use of other resources between groups. There was an expected significant difference between the 2 groups with respect to therapy charges, attributable to the fact that both nurses and respiratory therapists administered nebulized
-agonists on the control unit, while only nurses administered this therapy to patients on the clinical
pathway.
|
|
|
Adverse Events
Phone follow-up at 2 weeks was completed for 77 patients. The other patients either were lost to follow-up after discharge (n = 21) or had phone follow-up at 1 week, but not at 2 weeks after discharge (n = 12). Charts and electronic schedule records were reviewed for all patients, regardless of whether phone follow-up was completed. One patient in each group made a phone call to their care provider because of worsening asthma symptoms in the 2 weeks after discharge. Two patients in the control group had unscheduled clinic visits for asthma symptoms. No patients were admitted to the hospital in the 2 weeks after discharge. One control patient had a visit to the emergency department within the 2-week period with a chief complaint of wheezing but was free of symptoms and subsequently discharged after 3 nebulization therapies. There were no deaths in either group.
| |
DISCUSSION |
|---|
|
|
|---|
This study demonstrates that a clinical pathway for children with
asthma, using a nurse-driven weaning protocol adopted from nationally
accepted guidelines, significantly decreased the length of
hospitalization, the charges associated with the admission, and the
overall nebulized
-agonist use. What may seem to be a modest
decrease in the length of stay (13 hours) has significant implications
for an inpatient unit, in addition to the modest decrease in charges
incurred by each patient. Consider, for example, the impact that 13 additional hours in the hospital will have on bed availability. If we
assume that we admit 600 patients each year, with an average length of
stay of 53.7 hours, then these patients will occupy 600 beds for
31 800 hours. If we decrease the length of stay to an average of 40 hours, we will create 7800 hours of bed availability, which will make
room for 195 additional patients. From the perspective of an insurer,
this pathway will reduce the per-patient charges for an inpatient stay,
including inpatient physician professional fees, and medications. These families also would welcome other improvements that relate to a shorter
length of stay, including reducing costs associated with transportation
to and from the hospital, lost work hours, and potentially less
nosocomial spread of disease.
Our weaning protocol is based on clinical parameters suggested by the
NHLBI asthma guidelines.4 We asked primary nurses to wean
patients from nebulized
-agonist therapy in our institution because
our registered nurses are primarily responsible for obtaining vital
signs and administering these medications, and because we do not have
24-hour respiratory therapy on a consistent basis. Nevertheless, we
believe that either nurses or respiratory therapists could function in
this role, if they have been suitably educated and tested.
This is, to our knowledge, the first study demonstrating an impact of
an asthma clinical pathway on the length of stay. Two points should be
noted about this conclusion. The first point is that we reported a
length of stay in hours rather than in days, which is the more common
practice. Although many hospitals bill patients based on whether they
were present on a midnight census, this crude measure of length of stay
does not account for overall hospital census, which is a more accurate
depiction of activity. Using a length of stay measured in hours allows
us to recognize the potential for a higher overall number of
admissions. More admissions benefit both the hospital and any urgent
care facilities that might be holding patients in anticipation of a bed
becoming available. The second point is that at least one other study
by Kwan-Gett and colleagues17 reported an average length
of stay of 2 days, which is extremely short
3 days shorter than the
national median length of stay. The study by Kwan-Gett might have
suffered from a ceiling effect, making it less likely to show an
advantage to using clinical pathways even if one existed.
One of the interesting outcomes of the clinical pathway was a more
rapid weaning of bronchodilators in the intervention versus the control
group. By diminishing the duration of more frequent therapies, this
approach will decrease the time that the health care team spends
administering medications and checking vital signs
time that can be
spent assessing the patient and educating the patient and family. In
fact, the rapid weaning of bronchodilators could potentially relieve
nurse and respiratory staffing, because these patients can be managed
with a slightly lower nurse-to-patient ratio. Because more frequent
administration of albuterol is occasionally associated
with insomnia, tremor, agitation, hyperglycemia, hypokalemia, and
cardiac complications,19 more rapid weaning of
bronchodilators also will decrease the risk of iatrogenic
complications.
The intervention in this study was clearly more complex than simply
allowing nursing staff to have autonomy over the weaning of
-agonist
therapy. As shown in Table 1, the clinical pathway described an
approach to asthma education and discharge planning. Although this
study had insufficient power to determine whether the clinical pathway
reduced acute care encounters in the period after discharge, we are
reassured that our approach to education and discharge planning is
likely to decrease postdischarge symptoms. However, a larger study will
be needed to better estimate the effect of improved discharge planning
and asthma education.
One of the unanswered questions arising from this project is the effect
of clinical pathways on overall nursing workload. This pathway makes
nurses accountable for weaning the frequency of patient's medication
and educating patients and families. Rather than increasing the amount
of time a nurse spends with each patient, nurses who use this pathway
believe it optimizes their time. Nurses believe that it takes 5 minutes
to set up a nebulized bronchodilator therapy. Because we are able to
wean patients from more frequent therapy, we decrease the time nurses
are engaged in this activity. Nurses routinely have assessed patients
in our institution
the pathway allows them some autonomy in
decision-making based on their assessment. The education aspects of the
pathway should not increase nursing time, because our nurses have been
educating patients and families before we standardized the process. The less organized educational efforts that nurses used before the pathway
resulted in time spent finding all the necessary handouts and
determining what the patient had already been taught. Therefore, their
assessment of the pathway is that it saves time, rather than having the
opposite effect on their day.
Clinical pathways may affect patient care in other ways. For example, this pathway would be expected to increase the caseload of asthmatics in our hospital by making more beds available for admissions. The rapid admission and discharge of these patients will increase the intensity of care delivered by our nursing and resident staff. From the nursing perspective, more intense care demands higher staffing, which is unlikely to happen without a significant increase in patient acuity. From the standpoint of resident education, increased asthma admissions resulting from the pathway may or may not improve resident education. Taking on a more reactive stance toward medication weaning could detract from the educational goals of a residency, but admitting more patients with asthma could enhance the education about asthma. In the managed care era, this question becomes extremely important and should be the subject of additional study.
Study Limitations
This study was limited primarily by an inability to enroll some eligible patients because of bed shortages. Before patients could be approached about this study, a bed had to be available on both our intervention and control units. As the study proceeded, a high-inpatient census made beds largely unavailable. Therefore, in the interests of the patients, we chose to assign these patients to the first available bed rather than to enroll them in the study. There was no difference between the length of stay for these patients and for our control group. However, we had adequate power with our existing sample to detect a clinically significant difference in length of stay but not to detect a 20% or smaller difference in unplanned health care interventions. Therefore, the limited enrollment could disguise a negative effect that the clinical pathway might have had on unplanned health care interventions relative to our usual practice pattern.
Our intervention group had a higher percentage of patients who received steroids before their arrival to the ED. Although studies have shown that early use of steroids in an asthma exacerbation may reduce the need for hospitalization,20-23 few studies have evaluated whether such therapy affects the outcome of patients who are admitted.22 In our study, controlling for the administration of steroids before arrival by analysis of covariance was not associated with a shorter length of stay. There also was a statistically significant difference in the mean age of our 2 groups. However, there was no significant difference between the number of preschool children or adolescents in either group. In addition, analyzing our data with and without appropriate controls for steroid use and age did not significantly affect the outcome variables of interest.
Resident education about asthma has become an important topic at most academic medical centers. One possible confounder of this study is that residents could have become more knowledgeable about how best to manage patients with asthma during the study. Because any such improvement in asthma management should have been evident in both our control and intervention groups, it would have served to decrease rather than increase the differences in outcomes between these groups. A similar result should have been seen from any Hawthorne effect24 related to the fact that residents were aware that they and their patients were being studied.
Because the intervention unit had a smaller possible census than did the control units, the nursing ratio could have been more favorable for aggressive management of asthma at times (and less favorable at other times). This might have contributed to a lower length of stay and a more rapid weaning of patients. However, we are reassured by the lack of ED or inpatient encounters after these discharges, which suggest that patients did not experience a worsening of their symptoms after discharge.
Implications
This study provides further evidence of the value of guidelines such as those developed by the NHLBI. Such guidelines, when carefully evaluated and customized for a particular setting, can have a significant effect on the management of patients and on the outcomes of interest to patients, staff, and administrators. As in all cases, clinical pathways for diagnoses such as asthma can form a framework for performance improvement in a variety of areas. Clinical pathways also enable an institution to clearly identify processes that vary from an established guideline and to investigate whether these practices are associated with improved outcomes, worsened outcomes, or no change in outcomes. These investigations lead to adoption of new processes or recommendations to discontinue existing processes. In our institution, this study provided evidence to allow us to implement a new approach to asthma management throughout the institution. It confirmed our hypothesis that our nursing staff could safely and reliably assess patients and improve our ability to wean the frequency of their medications in a timely manner. Hopefully, additional studies based on the NHLBI guidelines will further improve our ability to manage this disease.
| |
ACKNOWLEDGMENTS |
|---|
This study was partially supported by the Johns Hopkins Miracle Telethon Funds (the Johns Hopkins Children's Center).
We thank Jeanne Butta, RN, for her assistance in data collection and analysis.
We thank Gerald Loughlin, MD, and Edward B. Chambers for their review of this manuscript.
| |
FOOTNOTES |
|---|
Received for publication Oct 25, 1999; accepted Feb 17, 2000.
Address correspondence to Kevin B. Johnson, MD, Division of General Pediatrics, The Johns Hopkins University School of Medicine, CMSC 140, 600 N Wolfe St, Baltimore, MD 21287-3144. E-mail: kjohnson{at}jhmi.edu
| |
ABBREVIATIONS |
|---|
NHLBI, National Heart, Lung, and Blood Institute; ED, emergency department.
| |
REFERENCES |
|---|
|
|
|---|
-
Taylor WR,
Newacheck PW
Impact of childhood asthma on health.
Pediatrics
1998;
90:657-662
[Abstract/Free Full Text] -
Gergen PJ,
Mullally DI,
Evans R
National survey of prevalence of asthma among children in the United States.
Pediatrics
1988;
8:1-7
[Abstract/Free Full Text] - Centers for Disease Control and Prevention, Vital and Health Statistics. Current Estimates From the National Health Interview Survey: 1996. Washington, DC: US Department of Health and Human Services, Public Health Service, National Center for Health Statistics; 1998. Department of Health and Human Services publication PHS 98-1232
- National Heart, Lung and Blood Institute. Expert Panel Report: Guideline for the Diagnosis and Management of Asthma. Washington, DC: US Department of Health and Human Services; 1991. Nation Institutes of Health publication 91-3042
- Weiss KB, Gergen PJ, Hodgson TA An economic evaluation of asthma in the United States. N Engl J Med 1992; 326:862-866 [Abstract]
-
Greineder DK,
Loane KC,
Parks P
Reduction in resource utilization by an asthma outreach program.
Arch Pediatr Adolesc Med
1995;
149:415-420
[Abstract/Free Full Text] - Zeiger RS, Heller S, Mellon MH, Wald J, Falkoff R, Schatz M Facilitated referral to asthma specialist reduced relapses in asthma emergency room visits. Allergy Clin Immunol 1991; 87:1160-1168 [CrossRef][Medline]
-
Hutton C
The use of clinical guidelines to improve medical practice: main issues in the United States.
Int J Qual Health Care
1997;
9:207-214
[Abstract/Free Full Text] -
Kitchiner D,
Bundred P
Integrated care pathways.
Arch Dis Child
1996;
75:166-168
[Free Full Text] -
Bailey R,
Weingarten S,
Lewis M,
Mohsenifar Z
Impact of clinical pathways and practice guidelines on the management of acute exacerbations of bronchial asthma.
Chest
1998;
113:28-33
[Abstract/Free Full Text] - Coffey RG, Richards JS, Remmert CS An introduction to critical paths. Qual Manag Health Care 1992; 1:45-54 [Medline]
- Eddy DM Clinical policies and the quality of clinical practice. N Engl J Med 1982; 307:343-347 [Medline]
- Goldberg R, Chan L, Haley P, Harmata-Booth J, Bass G Critical pathway for the emergency department management of acute asthma: effect on resource utilization. Ann Emerg Med 1998; 31:562-567 [CrossRef][Medline]
- Grimshaw JM, Russell IT Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342:1317-1322 [CrossRef][Medline]
- Lomas J Diffusion, dissemination, and implementation: who should do what? Ann N Y Acad Sci 1993; 703:226-235 [Medline]
- Schriefer J The synergy of pathways and algorithms: two tools work better than one. Jt Comm J Qual Improv 1994; 20:485-499 [Medline]
-
Kwan-Gett TS,
Lozano P,
Mullin K,
Marcuse EK
One-year experience with an inpatient asthma clinical pathway.
Arch Pediatr Adolesc Med
1997;
151:684-689
[Abstract/Free Full Text] - SPSS. Statistical Product and Service Solutions (SPSS) for Windows, Version 8.0.0. Chicago, IL: SPSS; 1997
- Papo MC, Frank J, Thompson AE A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993; 21:1479-1486 [Medline]
- Horowitz L, Zafrir O, Golboa S, Berger I, Wolach B Acute asthma: single dose oral steroids in paediatric community clinics. Eur J Pediatr 1994; 153:526-530 [CrossRef][Medline]
-
Scarfone FJ,
Fuchs SM,
Nager AL,
Shane SA
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Pediatrics
1993;
92:513-518
[Abstract/Free Full Text] - Wolfson DH, Nypaver MM, Blaser M, Hogan A, Evans R III, Davis AT A controlled trial of methylprednisolone in the early emergency department treatment of acute asthma in children. Pediatr Emerg Care 1994; 10:335-338 [Medline]
-
Grant CC,
Duggan AK,
DeAngelis C
Independent parental administration of prednisone in acute asthma: a double-blind, placebo-controlled, crossover study.
Pediatrics
1995;
96:224-229
[Abstract/Free Full Text] -
Parsons HM
What happened at Hawthorne?
Science
1974;
183:922-932
[Abstract/Free Full Text]
Pediatrics (ISSN 0031 4005). Copyright ©2000 by the American Academy of Pediatrics
This article has been cited by other articles:
![]() |
D. J. Zand, K. M. Brown, U. Lichter-Konecki, J. K. Campbell, V. Salehi, and J. M. Chamberlain Effectiveness of a Clinical Pathway for the Emergency Treatment of Patients With Inborn Errors of Metabolism Pediatrics, December 1, 2008; 122(6): 1191 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
British Thoracic Society Guideline Development Gro Intermediate care--Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline Thorax, March 1, 2007; 62(3): 200 - 210. [Full Text] [PDF] |
||||
![]() |
S P Norton, M V Pusic, F Taha, S Heathcote, and B C Carleton Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study Arch. Dis. Child., January 1, 2007; 92(1): 60 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Lemberg, A. S. Day, and M. Brydon The Role of a Clinical Pathway in Curtailing Unnecessary Investigations in Children With Gastroenteritis American Journal of Medical Quality, March 1, 2005; 20(2): 83 - 89. [Abstract] [PDF] |
||||
![]() |
S. Timmermans and A. Mauck The Promises And Pitfalls Of Evidence-Based Medicine Health Aff., January 1, 2005; 24(1): 18 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. McFadden Jr. Acute Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Wilson, B. B. Dahl, and R. D. Wells An Evidence-Based Clinical Pathway for Bronchiolitis Safely Reduces Antibiotic Overuse American Journal of Medical Quality, September 1, 2002; 17(5): 195 - 199. [Abstract] [PDF] |
||||
![]() |
C. Lau A clinical pathway reduced use of nebulised {beta} agonists and length of hospital stay in children with asthma exacerbations Evid. Based Nurs., April 1, 2001; 4(2): 44 - 44. [Full Text] |
||||
![]() |
J. H. Glauber, H. J. Farber, and C. J. Homer Asthma Clinical Pathways: Toward What End? Pediatrics, March 1, 2001; 107(3): 590 - 592. [Full Text] |
||||
![]() |
A Clinical Pathway for Pediatric Asthma Journal Watch (General), November 24, 2000; 2000(1124): 1 - 1. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||














